Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases. - Wikidata - awgldk - TriplyDB

Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.

Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.

http://www.wikidata.org/entity/Q37673360

about

The Imaging Diagnosis of Less Advanced Cases of Cardiac Amyloidosis: The Relative Apical Sparing Pattern

P2860

Q37697277-2BB5372D-C8C0-40C2-8EDD-B190105D25F9

P2860

Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.

http://www.wikidata.org/entity/Q37673360

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.

@en

Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.

@nl

type

label

Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.

@en

Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.

@nl

prefLabel

Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.

@en

Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.

@nl

P1433

Q37673360-C85C434B-D17A-4691-B1B0-CAD8FE8246F6

P1476

Q37673360-3E61D35B-128E-400E-A14A-8CCB33AEB0F4

P2093

Q37673360-41BA9B7C-9AC3-4E2C-8F65-3E70E0D6CD37

Q37673360-76152F77-7A8E-458E-8989-52004FC10BBE

Q37673360-832A4625-7566-4748-B96B-C3EE8DD2049B

Q37673360-CCE7D076-C5B3-43CA-9007-A1392A80111C

Q37673360-DC37CA46-D2E4-430B-B6EE-46AAE3AAA345

P2860

Q37673360-0CDB9C54-821C-4B35-9614-712DDA4A0CF2

Q37673360-2EAB896F-1A14-4C0E-8C9E-8EB9320CEFB0

Q37673360-35001158-911C-45C4-BAD2-CF1AE2F8E2F3

Q37673360-3E8750D4-76DE-4B2B-AFD3-0DC2B98BD73F

Q37673360-4EFCE863-BCD6-45B4-9789-27B1D8C199FF

Q37673360-597320B8-9AA1-4807-BA56-0C31EF22C510

Q37673360-5F9FB48F-7523-4A07-B1BC-22E08906A241

Q37673360-9A3E150C-FEB5-4869-A75D-69BFAB446AF9

Q37673360-C3BFEDD3-264F-45AC-A513-19C57BA837E2

Q37673360-EDE2A629-C4E7-4E73-9D8D-8F02CCC6C099

P304

Q37673360-7EDE26E2-7E3B-4AF5-B1FA-469262646B15

P31

Q37673360-1312AD7B-A95F-4D0A-867D-9DE4D24D7B6F

P356

Q37673360-BC15C07F-4E43-461F-8650-1623A8BCF38C

P478

Q37673360-049891A8-82BF-47A1-95AA-5FC2BAE51CE1

P577

Q37673360-77E9D0E7-F8AF-4869-98CC-B484815D5AF9

P5875

Q37673360-4DAE27DF-551D-4438-AB5E-84B3722863FD

P698

Q37673360-9557A9C4-CDD0-4C0D-9133-F2F45425F9E3

P932

Q37673360-AD6322C3-76C9-42D7-B389-AFE7E8293385

P356

P1433

Case Reports in Medicine

P1476

Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases.

@en

P2093

Francesco Pizzarelli

http://www.w3.org/2001/XMLSchema#string

Giuseppe Curciarello

http://www.w3.org/2001/XMLSchema#string

Piercarlo Ballo

http://www.w3.org/2001/XMLSchema#string

Santi Nigrelli

http://www.w3.org/2001/XMLSchema#string

Stefano Michelassi

http://www.w3.org/2001/XMLSchema#string

P2860

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.

Bortezomib in the treatment of AL amyloidosis: targeted therapy?

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

P304

627474

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/627474

http://www.w3.org/2001/XMLSchema#string

P478

2014

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261517837

http://www.w3.org/2001/XMLSchema#string

P698

24715916

http://www.w3.org/2001/XMLSchema#string

P932

3970246

http://www.w3.org/2001/XMLSchema#string